Simba Gill, PhD

Simba Gill, Ph.D., has served as a member of our Board of Directors since July 2017. He is currently the executive chairman of Serina Therapeutics and the executive chairman of Sensorium Therapeutics. Previously, Simba served as the president and chief executive officer of Evelo Biosciences, a Flagship VentureLabs^® company. During that time, he also served as the senior partner and special advisor at Flagship Pioneering, where he provided strategic counsel and support to portfolio companies.

Prior to his roles at Evelo and Flagship, Simba was a partner at TPG, a major private equity investor, where he focused on global healthcare and biotech investments. He has also held leadership roles at Roche/Boehringer Manheim. Earlier in his career, Simba held leadership roles at Roche and Boehringer Mannheim. Simba has founded and led multiple pioneering companies in the fields of antibodies, stem cells, directed molecular evolution, gene therapy and immunodiagnostics. Four of these companies became publicly traded and three were acquired through strategic transactions.

Simba holds his M.B.A. from INSEAD and received his Ph.D. from King’s College, London, where he focused on developing humanized antibodies to treat cancer in collaboration with Celltech.